Pharmacokinetic and pharmacodynamic characterization of non-antiarrhythmic QT-prolonging drugs associated with Torsades de Pointes

Drug Information Journal

Volumn 42, Issue 3, 2008, Pages 211-219

  Lin, Yeong Liang ^a,c   Chan, Keith ^b  

^a Center for Drug Evaluation   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NONE   (Taiwan)

Author keywords

Pharmacodynamic; Pharmacokinetic; QT prolongation; Torsades de Pointes

Indexed keywords

ALFUZOSIN; ARSENIC TRIOXIDE; ASTEMIZOLE; CISAPRIDE; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; HALOFANTRINE; ITRACONAZOLE; KETOCONAZOLE; METHADONE; MOXIFLOXACIN; NARATRIPTAN; PAROXETINE; PIMOZIDE; QUETIAPINE; SERTRALINE; TELITHROMYCIN; TERFENADINE; TERODILINE; THIORIDAZINE; VARDENAFIL; VORICONAZOLE; ZIPRASIDONE;

AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME INHIBITION; METABOLIC INHIBITION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; TORSADE DES POINTES;

EID: 44649153534     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150804200302     Document Type: Article

References (65)

1. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-arrhythmic drugs: clinical and regulatory implications: report on a policy conference of the European Society of Cardiology. Eur Heart J. 2000;21:1216-1231.
2. Anderson ME, Al Khatib SM, Roden DM, et al. Cardiac repolarization: current knowledge, critical gaps and new approaches to drug development and patient management. Am Heart J. 2002;144:769-781.
3. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. Geneva, Switzerland: International Conference on Harmonisation; 2005.
4. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. Geneva, Switzerland: International Conference on Harmonisation, 2005.
5. De Ponti F, Poluzzi E, Cavalli A, et al. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes. Drug Safety. 2002;25:263-286.
6. Owens RC Jr. Risk assessment for antimicrobial agent-induced QTc interval prolongation and Torsades de Pointes. Pharmacotherapy. 2001;21: 301-319.
7. US Food and Drug Administration. CDER drug and biological approval reports. Available at: http://www.fda.gov/cder/rdmt/default.htm. Accessed September 6, 2007.
8. US Food and Drug Administration. FDA drug approvals list. Available at: http://www.fda.gov/cder/da/da.htm. Accessed September 6, 2007.
9. US Food and Drug Administration. Drugs@FDA. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda. Accessed September 6, 2007.
10. Ketek. Physician's Desk Reference. 59th ed. Montvale, NJ: Thomson PDR; 2005: 710-715.
11. US Food and Drug Administration. Review of Ketek. Available at: http://www.fda.gov/cder/foi/nda/2004/21-144_Ketek_Medr_P2.pdf. Accessed September 6, 2007.
12. Demolis JL, Vacheron F, Cardus S, et al. Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects. Clin Pharmacol Ther. 2003;73:242-252.
13. Factive. Physician's Desk Reference. 59th ed. Montvale, NJ: Thomson PDR; 2005: 2554-2559.
14. US Food and Drug Administration. Review of Factive. Available at: http://www.fda.gov/cder/foi/nda/2003/21158_Factive_clinr_P2.pdf. Accessed September 6, 2007.
15. Ball P, Mandell L, Patou G, et al. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int J Antimicrob Agents. 2004;23:421-429.
16. Uroxatral. Physician's Desk Reference. 59th ed. Montvale, NJ: Thomson PDR; 2005: 3012-3015.
17. US Food and Drug Administration. Review of Uroxatral. Available at: http://www.fda.gov/cder/foi/nda/2003/21-287_Uroxatral_BioPharmr_P1.pdf. Accessed September 6, 2007.
18. Levitra. Physician's Desk Reference. 59th ed. Montvale, NJ: Thomson PDR; 2005: 845-848.
19. Carson CC. Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. Am J Cardiol. 2005;96(12B):31M-41M.
20. Amerge. Physician's Desk Reference. Montvale, NJ: Thomson PDR; 2005: 1408-1411.
21. US Food and Drug Administration. Review of Amerge. Available at: http://www.fda.gov/cder/foi/nda/98/20763_Amerge_Bioeqr.pdf. Accessed September 6, 2007.
22. Curtis LH, Østbye T, Sendersky V, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med. 2003;114: 135-141.
23. Seroquel. Physician's Desk Reference. Montvale, NJ: Thomson PDR; 2005: 662-667.
24. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004; 24:62-69.
25. Geodon. Physician's Desk Reference. Montvale, NJ: Thomson PDR; 2005: 2609-2615.
26. US Food and Drug Administration. Review of Geodon. Available at: http://www.fda.gov/cder/foi/nda/2001/20-825_Geodan_medr_P4.pdf. Accessed September 6, 2007.
27. Glassman AH. Antipsychotic drugs: prolonged QTc interval, Torsade de Pointes, and sudden death. Am J Psychiatry. 2001;158:1774-1782.
28. Goodnick PJ. Ziprasidone: profile on safety. Expert Opin Pharmacother. 2001;2:1655-1662.
29. Vfend. Physician's Desk Reference. Montvale, NJ: Thomson PDR; 2005: 2647-2656.
30. Justo D, Zeltser D. Torsade de Pointes induced by systemic antifungal agents: lessons from a retrospective analysis of published case reports. Mycoses. 2006;49:463-470.
31. Avelox. Physician's Desk Reference. Montvale, NJ: Thomson PDR; 2005: 815-821.
32. O'Donnell JA, Gelone SP. The newer fluoroquinolones. Infect Dis Clin North Am. 2004; 18:691-716.
33. Tequin. Physician's Desk Reference. Montvale, NJ: Thomson PDR; 2005: 1075-1082.
34. Bertino JS Jr, Owens RC Jr, Carnes TD, et al. Gatifloxacin-associated corrected QT interval prolongation, Torsades de Pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis. 2002;34:861-863.
35. Trisenox. Physician's Desk Reference. Montvale, NJ: Thomson PDR; 2005: 1099-1102.
36. Label of grepafloxacin. Available at: http://www.fda.gov/cder/foi/nda/98/ 20-695S003_Raxar_Prntlbl.pdf. Accessed September 6, 2007.
37. Lasser KE, Allen PD, Woodhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287: 2215-2220.
38. Pratt CM, Ruberg S, Morganroth J, et al. Dose-response relation between terfenadine and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J. 1996;131:472-480.
39. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA. 1993;269:1513-1518.
40. Label of Propulsid. Available at: http://www.fda.gov/cder/foi/nda/2000/ 20767-S011_Propulsid.pdf. Accessed September 6, 2007.
41. Khongphatthanayothin A, Lane J, Thomas D, et al. Effects of cisapride on QT interval in children. J Pediatr. 1998:133:51-56.
42. Lefebvre RA. Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. Br J Clin Pharmacol. 1997;47: 319-322.
43. Du Buske LM. Clinical comparison of histamine H1-receptor antagonist drugs. J Allergy Clin Immunol. 1996:98:S307-S318.
44. Vorperian VR, Zhou Z, Mohammad S, et al. Torsade de Pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardio. 1996:28:1556-1561.
45. Hartigan-Go K, Bateman DN, Nyberg G, et al. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther. 1996;60:543-553.
46. Bednar MM, Harrigan EP, Ruskin JN. Torsades de Pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol. 2002;89:1316-1319.
47. von Bahr C, Movin G, Nordin C, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther. 1991;49:234-240.
48. Carrillo JA, Ramos SI, Herraiz AG, et al. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J Clin Psychopharmacol. 1999;19:494-499.
49. Sallee FR, Poock BG, Stiller RL, et al. Pharmacokinetics of pimozide in adults and children with Tourette's syndrome. Clin Pharmacol. 1987;27: 776-781.
50. Alderman J. Coadministration of sertraline with cisapride or pimozide: an open-label nonrandomized examination of pharmacokinetics and corrected QT intervals in healthy adult volunteers. J Clin Ther. 2005;27:1050-1063.
51. Flockhart DA, Drici MD, Kerbusch T, et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol. 2000;20: 317-324.
52. Fulop G, Phillips RA, Shapiro AK, et al. ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry. 1987;144:673-675.
53. Tennyson H, Levine N. Neurotropic and psychotropic drugs in dermatology. Dermatol Clin. 2001;19:179-197
54. Label of Halfan. Available at: http://www.fda.gov/cder/foi/label/2002/ 20250s7s8lbl.pdf. Accessed September 6, 2007.
55. Charbit B, Becquemont L, Lepere B, et al. Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. Clin Pharmacol Ther. 2002;72:514-523.
56. Gupta A, Lawrence AT, Krishnan K, et al. Current concepts in the mechanisms and management of drug-induced QT prolongation and Torsade de Pointes. Am Heart J. 2007;153:891-899.
57. Label of Methadose. Available at: http://www.fda.gov/cder/foi/label/2005/ 017116s015,016lbl.pdf. Accessed September 6, 2007.
58. Hallen B, Gabrielsson J, Nyambati S, et al. Concomitant single-dose and multiple-dose pharmacokinetics of terodiline in man, with a note on its enantiomers and major metabolites. Pharmacol Toxicol. 1995;76:171-177.
59. Sparf B. Pharmacodynamics and pharmacokinetics of terodiline. Urology. 1990;36(4 suppl): 44-49.
60. Aria N, Kauffman LC. Important drug interactions and reactions in dermatology. Dermatol Clin. 2003;21:207-215.
61. Roden DM. Drug-induced prolongation of the QT interval. New Engl J Med. 2004;350:1013-1022.
62. Naccarelli GV, Lee KS, Gibson JK, et al. Electrophysiology and pharmacology of ibutilide. Am J Cardiol. 1996;78(suppl):12-16.
63. Kowey PR, Marinchak RA, Rials SJ, et al. Classification and pharmacology of antiarrhythmic drugs. Am Heart J. 2000;140:12-20.
64. Roden DM, Lazzara R, Rosen M, et al. Multiple mechanisms in the long-QT syndrome. Current knowledge, gap, and future directions. Circulation. 1996;94:1996-2012.
65. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation. 1998;98:2334-2351.